NEWS

Go back

Go to

Healthcare Focused Private Equity Firm ARCHIMED Closes Second Fund, at €315M

 September

 18, 

2017

ARCHIMED, a Lyon, France-based investment firm focused on healthcare, closed its second fund, at €315m.

The Med II Fund went through a four-month fundraising campaign with LPs including nearly 30 investors such as endowments, foundations, funds-of-funds, family offices, banks, insurers and sovereign wealth funds investors, mainly from the United States and Europe.

Formed in 2014 by former 3i Healthcare leaders, ARCHIMED is a lower midmarket private equity firm focused exclusively on healthcare investments, engaging in both unleveraged growth investments and leveraged buyouts. It invests between €5m and €50m per transaction in all healthcare sectors, including Medtech, Biopharma, Care Services and Preventive Healthcare.

Led by Denis Ribon, Vincent Guillaumot, Robin Filmer-Wilson, Loïc Kubitza and operating partner Christoph Böhmer, ARCHIMED is currently the reference shareholder of Swiss-Italian company Medistream, French firms Polyplus and Fytexia, British firms Deallus and RehabWorks, Italian-French company Micromed and Italian company Primo. The inaugural Med I fund raised €150m.

Source: FinSMEs

About ARCHIMED

archimed.group

With offices in the US and Europe, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to North American and European healthcare businesses.
Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services.
ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ARCHIMED’s leadership team has directly managed and invested in over eighty small to large-size healthcare companies globally, representing over €50 billion of combined value. ARCHIMED manages €5 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

ARCHIMED Press Contacts

France: Stéphanie du Ché
stephanie.duche@archimed.group
+33 (0)6 16 36 11 08

International: David Lanchner
dlanchner@lanchner.com,
+33 (0)6 33 43 50 76